Sanazole as a sensitizer of hypoxic cells with radical radiation in the treatment of advanced cancer of cervix an Indian experience.

Abstract

AK-2123, is a nitrotriazole with a potential to sensitize hypoxic tissue to radiation. Cancer of cervix in advanced stages are predominantly treated with radiation. These are the tumours which harbour a large hypoxic core. This is an Indian experience of the multicentric trial. Patients were randomized to control and AK-2123 arm. 49 patients were randomized to each group. Patients received external radiation with telecobalt to a dose of 50 Gy in five weeks. Those in the study arm received 600 mg/m2, on alternate days. The patients were further treated with intracavitory radiation a dose of 20 Gy. The total dose of 70 Gy was achieved. Patients in the study arm had a complete response of 71.43% (35 of 49) while only 21 of 49 (42.86%) responded in the control group. The overall survival at two years was 72.2% for the study group and 32.43% for control. Neuropathy, a drug related toxicity was transient except, in one patient, which has persisted. AK-2123, has shown significant radiation sensitizing potential.

• Authors: Nagraj G Huilgol, Werner Dobrowsky, Hideo Tatsuzaki, Neela A Chatterjee, V T Kagiya, Kaushik Das
• Journal: Indian journal of cancer (Indian J Cancer) Vol. 39 Issue 2 Pg. 39-44 (Jun 2002) ISSN: 0019-509X [Print] India
• PMID: 12789723 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Radiation-Sensitizing Agents
• Triazoles
• AK 2123

Topics

• Adult
• Aged
• Female
• Humans
• India (epidemiology)
• Middle Aged
• Nervous System Diseases (etiology)
• Radiation-Sensitizing Agents (adverse effects, therapeutic use)
• Radiotherapy Dosage
• Survival Rate
• Triazoles (adverse effects, therapeutic use)
• Uterine Cervical Neoplasms (drug therapy, mortality, radiotherapy)